This press release is a routine scientific publication with no immediate trading catalyst. Monitor for upcoming clinical data readouts or regulatory milestones for INB-100, INB-200/400, or INB-600 platform.
Price Chart
Executive Summary
IN8bio announced the publication of a review article in Nature Communications co-authored by its CSO, highlighting advances in gamma-delta T cell engineering and combination therapies. The publication is a non-clinical, academic milestone that does not provide new clinical data or regulatory catalysts, and is unlikely to materially impact the stock.
Key Facts
- Review article published in Nature Communications, co-authored by IN8bio CSO Lawrence Lamb, Ph.D.
- Publication discusses gamma-delta T cell engineering, combination strategies, and clinical development approaches.
- No new clinical data, regulatory decisions, or financial guidance were announced.
- IN8bio is a clinical-stage biopharmaceutical company with a market cap of approximately $15M.
Financial Impact
No financial impact; the publication is a non-commercial academic review.
Risk Factors
- No new clinical data or regulatory catalysts provided.
- Early-stage biotech with limited pipeline and high cash burn risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | Press Release | $1.54 $1.04 | ▼ −32.47% | ▼ −34.97% | $0.9655 (−37.31%) |
Jun 1, 2026 21w ago | 8-K | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9655 (+44.19%) |
Jun 1, 2026 21w ago | 424B5 | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9655 (+44.19%) |
May 18, 2026 22w ago | S-3/A | $1.45 $1.18 | ▲ +18.62% | ▲ +24.91% | $0.9655 (+33.41%) |
May 7, 2026 24w ago | 8-K | $1.58 $0.9601 | ▼ −39.23% | ▼ −44.07% | $0.9655 (−38.89%) |
Mar 26, 2026 30w ago | DEFA14A | $1.41 $1.51 | ▲ +7.09% | ▼ −8.97% | $0.9655 (−31.52%) |
Mar 12, 2026 32w ago | Press Release | $1.89 $1.44 | ▼ −23.81% | ▼ −35.42% | $0.9655 (−48.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers